The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations

Table 2 The association between MAFLD and sarcopenia

	MAFLD			MAFLD Phenotypes						Fibrosis
	OR^a	95% CI	p-value	with Mild Steatosis			with Moderate and Severe Steatosis			OR^a	95% CI	p-value
	OR^a	95% CI	p-value	OR^a	95% CI	p-value	OR^a	95% CI	p-value	OR^a	95% CI	p-value
Model1^b	3.77	2.55–5.56	< 0.001	1.06	0.81–1.39	0.638	1.32	0.87–2.02	0.179	2.18	1.30–3.64	0.006
Model2^c	2.74	1.81–4.13	< 0.001	0.91	0.65–1.29	0.567	2.06	1.12–3.81	0.026	2.27	1.35–3.82	0.007
Model3^d	2.82	1.71–4.63	0.004	3.36	1.97–5.73	0.002	3.36	1.59–7.13	0.009	2.17	1.19–3.95	0.021
Model4^e	2.87	1.62–5.09	0.010	3.45	1.93–6.18	0.004	3.49	1.60–7.64	0.001	2.16	1.13–4.15	0.030

^aOR = Odds Ratio, CI = Confidence Interval
^bCrude model
^cAdjusted for age, race, and sex. For MAFLD with mild steatosis, adjusted for race and sex; for MAFLD with moderate and severe steatosis, adjusted for age and race
^dFurther adjusted for smoking and alcohol drinking status. For fibrosis, further adjusted for alcohol drinking status
^eFurther adjusted for sedentary activity

ISSN: 1471-230X